Skip to content

UroGen Pharma URGN Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$133.23M+13.2%-$153.49M+6.8%-$164.64M-6.2%-$154.97M-11.9%-$138.43M-9.1%
$350K+0.9%$347K+2.1%$340K0.0%$340K0.0%$340K-13.0%
$13.52M+13.0%$11.96M-1.4%$12.13M-3.7%$12.59M-6.2%$13.42M+2.4%
-$165.74M-2.0%-$162.44M-17.9%-$137.74M-11.9%-$123.13M-15.0%-$107.06M-10.6%
$299K+3.5%$289K-25.3%$387K-2.3%$396K+16.8%$339K+14.9%
$66.83M+8.6%$61.56M
$18.37M-25.0%
$105.09M+163%$39.92M+360%$8.67M-78.3%$40.01M-71.4%$140M-28.1%
-$34.6M
-$166.04M-2.0%-$162.73M-17.8%-$138.13M-11.8%-$123.53M-15.0%-$107.39M-10.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does UroGen Pharma generate?
UroGen Pharma (URGN) generated -$165.7M in operating cash flow over the trailing twelve months.
What is UroGen Pharma's free cash flow?
After $299.0K of capital expenditures, UroGen Pharma's free cash flow was -$166.0M over the trailing twelve months, down 54.6% year over year.
Where does UroGen Pharma's cash flow data come from?
Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.